3-Methyl-PCPy is an arylcyclohexylamine derivative with an unusual spectrum of pharmacological effects, acting as both a potent NMDA antagonist and also a triple reuptake inhibitor which inhibits reuptake of all three monoamine neurotransmitters serotonin, dopamine and noradrenaline. It also acts as a high affinity sigma receptor ligand, selective for the σ2 subtype.
--This is an extremely interesting profile.
It produces both stimulant and dissociative effects in animal behavioural studies.
3-Methyl-PCPy is covered by drug analogue laws in various jurisdictions (UK, Germany, Japan, Australia etc) as a generic arylcyclohexylamine derivative, and a structural isomer of phencyclidine.
References 1-3, from wikipedia:
Wallach J, De Paoli G, Adejare A, Brandt SD (2014). "Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues". Drug Testing and Analysis. 6 (7–8): 633–50. doi:10.1002/dta.1468. PMID 23554350.
Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–32. doi:10.1002/dta.1620. PMID 24678061.
Wallach J, Brandt SD (2018). "Phencyclidine-Based New Psychoactive Substances". Handbook of Experimental Pharmacology. 252: 261–303. doi:10.1007/164_2018_124. ISBN 978-3-030-10560-0. PMID 30105474.